Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on February 3, 2026 to new hires under its Amended and Restated 2014 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Four employees received stock options for an aggregate of 58,000 shares (10-year term, $21.02 exercise price, four-year vesting). Fourteen employees received restricted stock units representing an aggregate of 41,300 shares (vesting annually over four years beginning February 1, 2027). Vesting is subject to continued employment and award agreements.

Key Figures

Inducement option shares: 58,000 shares Inducement RSU shares: 41,300 shares Option exercise price: $21.02 per share +5 more

8 metrics

Inducement option shares 58,000 shares Stock options granted to four employees on Feb 3, 2026

Inducement RSU shares 41,300 shares Restricted stock units granted to 14 employees on Feb 3, 2026

Option exercise price $21.02 per share Closing price on Nasdaq Global Select Market on grant date

Option term 10 years Term of the stock options granted under Inducement Plan

Initial vesting portion 25 percent Options vest on first anniversary of employment start date

Employees receiving awards 14 employees New hires receiving inducement awards on Feb 3, 2026

Current share price $21.00 Price before publication of inducement grant news

Price change 24h 3.14% Move in the 24 hours prior to the news

Market Reality Check

Price: $21.07 Vol: Volume 524,259 is 0.51x t...

low vol

$21.07 Last Close

Volume Volume 524,259 is 0.51x the 20-day average of 1,032,470, indicating lighter-than-usual trading before this news. low

Technical Shares at $21.00 were trading below the 200-day MA of $24.15, and about 24.02% under the 52-week high of $27.64 yet 11.7% above the 52-week low of $18.80.

Peers on Argus

PCRX was up 3.14% while closely ranked peers like COLL, DVAX, AMPH, AVDL, and HR...

PCRX was up 3.14% while closely ranked peers like COLL, DVAX, AMPH, AVDL, and HROW showed smaller positive moves between 0.06% and 2.27%. No peers appeared in the momentum scanner and there were no same-day peer headlines, pointing to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Board appointment	Positive	+2.7%	Added experienced director and expanded board to ten members.
Jan 13	Commercial partnership	Positive	-5.8%	Exclusive EXPAREL commercialization agreement with LG Chem in Asia-Pacific.
Jan 08	Preliminary revenues	Positive	+0.1%	Reported higher 2025 revenues and Q4 share repurchases with cash remaining.
Jan 07	Conference presentation	Neutral	+2.7%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast.
Dec 30	Governance challenge	Neutral	+0.0%	DOMA Perpetual Capital signaled intent to nominate new director candidates.

Pattern Detected

Recent news has drawn mixed reactions: several positive items aligned with modest gains, while some commercial and event headlines saw price moves that diverged from their generally positive tone.

Recent Company History

Over the past few months, Pacira announced board expansion with Dr. Samit Hirawat on Jan 28, 2026, which coincided with a 2.67% gain. Commercial updates have been frequent: a distribution agreement for EXPAREL in Asia-Pacific on Jan 13, 2026 saw a -5.8% move despite its growth focus, while preliminary 2025 revenues of $726.4 million and share repurchases reported on Jan 8, 2026 had a nearly flat reaction. The current inducement grants continue a pattern of ongoing equity-based compensation and hiring activity noted in early January.

Market Pulse Summary

This announcement details routine inducement equity awards to 14 new employees, including 58,000 sto...

Analysis

This announcement details routine inducement equity awards to 14 new employees, including 58,000 stock options and 41,300 restricted stock units at an exercise price of $21.02. It follows prior disclosures of inducement grants and insider equity activity, underscoring Pacira’s use of stock-based compensation in talent recruitment. Investors monitoring governance and dilution risk may track future equity award disclosures alongside the company’s revenue trends and board-level changes highlighted in recent filings and press releases.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"14 employees received restricted stock units for an aggregate of 41,300 shares..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"The stock options have an exercise price of $21.02 per share..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Four employees received stock options to purchase an aggregate of 58,000 shares of Pacira common stock and 14 employees received restricted stock units for an aggregate of 41,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $21.02 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on February 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com

FAQ

What inducement awards did Pacira (PCRX) grant on February 3, 2026?

Pacira granted stock options and restricted stock units to new hires as inducement awards. According to the company, four employees received options totaling 58,000 shares and 14 employees received RSUs totaling 41,300 shares, approved under Nasdaq Rule 5635(c)(4).

What are the key terms of the Pacira (PCRX) stock options granted on February 3, 2026?

The stock options have a 10-year term and a four-year vesting schedule with an exercise price of $21.02. According to the company, 25% vests on the first anniversary, then equal quarterly installments over the following 36 months.

When do the restricted stock units from Pacira (PCRX) begin vesting and what is the schedule?

The RSUs vest annually over four years beginning on February 1, 2027. According to the company, each RSU represents the contingent right to receive one share and vesting is conditioned on continued employment and award agreement terms.

Why were the Pacira (PCRX) inducement awards approved without shareholder approval?

The awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for new employees. According to the company, the People & Compensation Committee approved the grants without shareholder approval consistent with that Nasdaq rule.

How many employees received inducement equity from Pacira (PCRX) and what is the total share count?

Pacira granted inducement equity to new hires: 14 employees received RSUs and 4 employees received options. According to the company, the aggregate awards cover 99,300 shares (58,000 options and 41,300 RSUs).